Characteristics | All patients (n = 90) 5% of all breast cancers (n = 1800) | Patients with nonmetastatic disease (n = 72) |
---|---|---|
Patient’s characteristics | ||
Age | ||
Median | 47 | 47 |
Range | 29 - 75 | 29 - 75 |
Menoposal status | ||
Premenoposal | 51 (56.7%) | 38 (53%) |
Postmenoposal | 34 (37.8%) | 30 |
Unknown | 5 | 4 |
Histilogy | ||
Infiltrating ductal carcinoma | 84 (93.3%) | 69 (96%) |
Infiltrating lobular carcinoma | 3 (3.3%) | 2 |
Other | 3 (3.3%) | 3 |
SBR | ||
I | 5 (5.6%) | 4 |
II | 45 (50%) | 36 |
III | 24 (26.7%) | 20 |
Unknown | 16 (17.7%) | 12 |
Hormone receptor status | ||
ER+/PR+ | 37 | 30 |
ER+/PR- | 0 | 0 |
ER-/PR+ | 23 | 19 (26.4%) |
ER-/PR- | 4 | 4 (5.6%) |
Unknown | 26 | 19 |
HER2/neu status | ||
Positif | 23 (25.5%) | 18 (25%) |
Negatif | 22 | 20 |
Unknown | 45 | 34 |
Clinical stage N | ||
N0 | 31 (34.4%) | 23 (32%) |
N1 | 42 (46.7%) | 33 |
N2 | 12 (13.3%) | 12 |
N3 | 5 (5.6%) | 4 |
Clinical stage M | ||
M0 | 72 (80%) | 72 |
M1 | 18 (20%) | 0 |
Taxanes | ||
Yes | 45 | 37 (51.4%) |
No | 43 | 35 (48.6%) |
Unknown | 2 | 0 |
Surgery | ||
Yes | 53 | 51 (71%) |
No | 37 | 21 (29%) |
Radiotherapy | ||
Yes | 40 | 39 (54%) |
No | 50 | 33 (36%) |
cOR (CR + PR) | - | 49 (68%) |
pCR | - | 1 (1.4%) |
Pathologically negative lymph nodes | 5 (7%) | |
1 and 2 y LRRFS | - | 90.8%; 78.1% |
1 and 2 y EFS | - | 81.7%; 57.5% |
1 and 2 y OS | - | 94.3%; 74.6% |